Complix NV
Technologiepark 94
9052 Zwijnaarde
BE
Complix NV
Foundation date
23/06/2008
Sector
#Biotechnology - TherapeuticsSubsector
Therapeutic areas
- #Cardiovascular
- #Diseases of the blood and blood-forming organs - immune disorders
- #Infectious and parasitic diseases
- #Neoplasms / cancer / oncology
Complix is a biopharmaceutical company engaged in the discovery and development of Alphabodies™, a revolutionary class of biopharmaceuticals with exceptional properties. Alphabodies™ combine beneficial properties of small molecules with those of antibodies, and can address intracellular as well as extracellular disease targets that are undruggable by antibodies or small chemical drugs. Complix has developed a balanced pipeline of transformative protein therapeutics in oncology, autoimmunity/inflammation and viral diseases.
Upcoming events
All events-
0411 '24
BIO-Europe® 2024 - 30th Annual International Partnering Conference
Event by: EBD Group -
1012 '24
Next-Generation Synthetic Biology
Event by: VIB -
0312 '24
BioFIT 2024
Event by: Eurasanté
Latest news
More newsJobs
More jobs-
-
-
30/10/24
Flemish Brabant
Professor in Food Microbiology: Applications of microbes in the food chain (ref. ZAP-2024-87)
Permanent
KU Leuven
More info?
Ellen Telleir
Communication Coordinator